Genen­tech and Bio­gen pen roy­al­ty deal for blood can­cer drug with big po­ten­tial

Bio­gen’s col­lab­o­ra­tion with Genen­tech could pay off again in the form of US roy­al­ties for the po­ten­tial blood can­cer drug glofi­ta­m­ab, a CD20xCD3 bis­pe­cif­ic. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER